These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32734559)

  • 21. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
    Lovshin JA
    Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction.
    Liu Z; Bian N; Wu S; Fan Y; Li H; Yu J; Guo J; Chen D
    Front Cardiovasc Med; 2022; 9():1019120. PubMed ID: 36277800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
    Karakasis P; Patoulias D; Pamporis K; Stachteas P; Bougioukas KI; Klisic A; Fragakis N; Rizzo M
    Metabolism; 2023 Dec; 149():155710. PubMed ID: 37852529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis.
    Krisanapan P; Suppadungsuk S; Sanpawithayakul K; Thongprayoon C; Pattharanitima P; Tangpanithandee S; Mao MA; Miao J; Cheungpasitporn W
    Clin Kidney J; 2024 Feb; 17(2):sfae018. PubMed ID: 38410684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Ding L; Sun B; Xiao X
    Int J Endocrinol; 2020; 2020():1626484. PubMed ID: 33061964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Wang W; Liu H; Xiao S; Liu S; Li X; Yu P
    Diabetes Ther; 2017 Aug; 8(4):727-738. PubMed ID: 28616805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.
    Alfayez OM; Almutairi AR; Aldosari A; Al Yami MS
    Can J Diabetes; 2019 Oct; 43(7):538-545.e2. PubMed ID: 31175007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials.
    Salamah HM; Marey A; Abugdida M; Abualkhair KA; Elshenawy S; Elhassan WAF; Naguib MM; Malnev D; Durrani J; Bailey R; Tsyunchyk A; Ibrahim L; Zavgorodneva Z; Sherazi A
    Diabetol Metab Syndr; 2024 Jun; 16(1):129. PubMed ID: 38877565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.
    Al Yami MS; Alfayez OM; Alsheikh R
    Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.
    Kim HJ; Park SO; Ko SH; Rhee SY; Hur KY; Kim NH; Moon MK; Lee BW; Kim JH; Choi KM;
    Diabetes Metab J; 2017 Dec; 41(6):423-429. PubMed ID: 29272081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of glucagon-like peptide-1 receptor agonists on patients with heart failure: a meta-analysis of randomized controlled trials.
    Obata S; Miyamoto Y; Slipczuk L; Takagi H; Kuno T
    J Cardiovasc Med (Hagerstown); 2023 Feb; 24(2):132-137. PubMed ID: 36583981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
    Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis.
    Chen X; Zhao P; Wang W; Guo L; Pan Q
    Am J Geriatr Psychiatry; 2024 Jan; 32(1):117-127. PubMed ID: 37684186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis.
    Patoulias D; Papadopoulos C; Siskos F; Stavropoulos K; Doumas M
    Blood Press Monit; 2021 Aug; 26(4):284-287. PubMed ID: 33741774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Kristensen SL; Rørth R; Jhund PS; Docherty KF; Sattar N; Preiss D; Køber L; Petrie MC; McMurray JJV
    Lancet Diabetes Endocrinol; 2019 Oct; 7(10):776-785. PubMed ID: 31422062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials.
    Rivera FB; Cruz LLA; Magalong JV; Ruyeras JMMJ; Aparece JP; Bantayan NRB; Lara-Breitinger K; Gulati M
    Am J Prev Cardiol; 2024 Jun; 18():100679. PubMed ID: 38779187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The correlations between steady-state concentration, duration of action and molecular weight of GLP-1RAs and their efficacy and gastrointestinal side effects in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Jiao R; Lin C; Bai S; Cai X; Hu S; Lv F; Yang W; Zhu X; Ji L
    Expert Opin Pharmacother; 2023 Mar; 24(4):511-521. PubMed ID: 36799287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.